Lilly to showcase advances across its oncology pipeline at the 2026 European Society for Medical Oncology (ESMO) Congress
First Phase 1 data for sofetabart mipitecan, Lilly's investigational FRα-targeting ADC, in platinum-sensitive ovarian cancer to be featured in a rapid oral presentation Updated first-line data for olomorasib, an investigational therapy targeting KRAS G12C-mutant NSCLC, to be featured in a...
Covered in this story
What has happened since
- Agree Realty is up 1.6% since this was published.
Price move measured from the close nearest publication to the latest quote.
Call it yourself
No calls on $ADC yet. A scorecard is a price target with a date and the working behind it — tracked, settled and scored in public.
Make the first call on Agree Realty →Summary aggregated from PR Newswire's public RSS feed. The full reporting belongs to PR Newswire — please read it on their site.